Novartis Vaccines will increase the supply of its Fluvirin vaccine 30% for distribution in the U.S. during the 2007-2008 flu season and plans to produce approximately 40 million doses. Based on accelerated production plans, half of these doses are planned for September delivery, with all doses expected to be delivered by the end of October, depending on the release of doses by the FDA.  
   
"Providing a reliable and timely supply of flu vaccines is a top priority for Novartis in supporting U.S. public health goals of increasing vaccination rates among the growing number of people at risk and recommended for vaccination," said Rajiv De Silva, president of Novartis Vaccines in the U.S.